Arcutis Biotherapeutics, INC Form 4 insider transactions

Arcutis Biotherapeutics CEO, Todd Franklin Watanabe, acquired additional shares of company stock through the Employee Stock Purchase Plan and other transactions.

Arcutis Biotherapeutics' Senior Vice President and Chief Medical Officer, Patrick Burnett, exercised stock options and sold shares on November 22, 2024.

Arcutis Biotherapeutics' Senior Vice President, Masaru Matsuda, sold shares to cover tax obligations after performance stock units vested.

An Arcutis Biotherapeutics executive, Patrick Burnett, sold shares after exercising stock options, according to a recent SEC filing.

Director Terrie Curran sold 8,687 shares of Arcutis Biotherapeutics stock at an average price of $10.8482 on November 11, 2024.

Masaru Matsuda, an executive at Arcutis Biotherapeutics, sold 5,015 shares of common stock to cover tax obligations related to vesting restricted stock units.

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 13,871 shares of common stock on November 4, 2024, to cover tax obligations related to the vesting of Restricted Stock Units.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock on November 1, 2024, at a weighted average price of $8.6541 per share, according to a Form 4 filing with the SEC.

Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 15,441 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock on October 1, 2024, at a weighted average price of $9.2616 per share, according to a Form 4 filing with the SEC.

Larry Todd Edwards, SVP and Chief Commercial Officer of Arcutis Biotherapeutics, sold 3,725 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Arcutis Biotherapeutics' CFO, David Topper, reports acquisition and disposal of common stock related to performance stock units (PSUs) vesting and subsequent sell-to-cover transactions.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock at an average price of $10.7695, pursuant to a pre-arranged 10b5-1 trading plan.

Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, sold shares to cover tax obligations related to vesting restricted stock units.

Masaru Matsuda, Senior Vice President and General Counsel of Arcutis Biotherapeutics, sold 5,220 shares of common stock on August 2, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 13,206 shares of common stock on August 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Todd Franklin Watanabe, CEO of Arcutis Biotherapeutics, sold 14,487 shares of common stock on August 2, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Director Howard G. Welgus exercised stock options and sold shares of Arcutis Biotherapeutics (ARQT) on August 1, 2024, according to a Form 4 filing with the SEC.

Director Howard G. Welgus reports exercising stock options and selling shares of Arcutis Biotherapeutics, Inc. on July 1, 2024.

Director Keith Leonard reports acquisition of Arcutis Biotherapeutics shares and stock options related to his service as a non-employee director.

Director Howard G. Welgus reports acquisition of Arcutis Biotherapeutics stock and options related to his service as a non-employee director.

Director Patrick J. Heron reports acquisition of common stock and stock options in Arcutis Biotherapeutics.

Director Terrie Curran reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Director Neha Krishnamohan reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Director Sue-Jean Lin reports acquisition of restricted stock units and stock options in Arcutis Biotherapeutics.

Director Halley E. Gilbert reports acquisition of restricted stock units and stock options in Arcutis Biotherapeutics.

Director Bhaskar Chaudhuri reports acquisition of restricted stock units and stock options in Arcutis Biotherapeutics.

Director Howard G. Welgus of Arcutis Biotherapeutics reports the exercise of stock options and subsequent sale of common stock on June 4, 2024.

Patrick Burnett, SVP and Chief Medical Officer of Arcutis Biotherapeutics, sold shares of common stock after exercising stock options.

Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, sold shares to cover tax obligations related to vesting performance stock units.